BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND PALB2, ENSG00000083093, 79728 AND Treatment
8 results:

  • 1. Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and palb2 in a tumor-Only Genomic Testing Program.
    Bychkovsky BL; Li T; Sotelo J; Tayob N; Mercado J; Gomy I; Chittenden A; Kane S; Stokes S; Hughes ME; Kim JS; Umeton R; Awad MM; Konstantinopoulos PA; Yurgelun MB; Wolpin BM; Taplin ME; Newmark RE; Johnson BE; Lindeman NI; MacConaill LE; Garber JE; Lin NU
    Clin Cancer Res; 2022 Jun; 28(11):2349-2360. PubMed ID: 35363308
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Therapeutic Implications of germline Testing in Patients With Advanced Cancers.
    Stadler ZK; Maio A; Chakravarty D; Kemel Y; Sheehan M; Salo-Mullen E; Tkachuk K; Fong CJ; Nguyen B; Erakky A; Cadoo K; Liu Y; Carlo MI; Latham A; Zhang H; Kundra R; Smith S; Galle J; Aghajanian C; Abu-Rustum N; Varghese A; O'Reilly EM; Morris M; Abida W; Walsh M; Drilon A; Jayakumaran G; Zehir A; Ladanyi M; Ceyhan-Birsoy O; Solit DB; Schultz N; Berger MF; Mandelker D; Diaz LA; Offit K; Robson ME
    J Clin Oncol; 2021 Aug; 39(24):2698-2709. PubMed ID: 34133209
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors.
    Lobo J; Constâncio V; Guimarães-Teixeira C; Leite-Silva P; Miranda-Gonçalves V; Sequeira JP; Pistoni L; Guimarães R; Cantante M; Braga I; Maurício J; Looijenga LHJ; Henrique R; Jerónimo C
    Mol Oncol; 2021 Apr; 15(4):846-865. PubMed ID: 33513287
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors.
    Han J; Yu M; Bai Y; Yu J; Jin F; Li C; Zeng R; Peng J; Li A; Song X; Li H; Wu D; Li L
    Cancer Cell; 2020 Dec; 38(6):844-856.e7. PubMed ID: 33186520
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Successful BRAF/MEK inhibition in a patient with
    Busch E; Kreutzfeldt S; Agaimy A; Mechtersheimer G; Horak P; Brors B; Hutter B; Fröhlich M; Uhrig S; Mayer P; Schröck E; Stenzinger A; Glimm H; Jäger D; Springfeld C; Fröhling S; Zschäbitz S
    Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843432
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
    Kadouri L; Rottenberg Y; Zick A; Hamburger T; Lipson D; Peretz T; Nechushtan H
    Lung Cancer; 2019 Nov; 137():48-51. PubMed ID: 31542568
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Response to olaparib in a
    Horak P; Weischenfeldt J; von Amsberg G; Beyer B; Schütte A; Uhrig S; Gieldon L; Klink B; Feuerbach L; Hübschmann D; Kreutzfeldt S; Heining C; Maier S; Hutter B; Penzel R; Schlesner M; Eils R; Sauter G; Stenzinger A; Brors B; Schröck E; Glimm H; Fröhling S; Schlomm T
    Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30833416
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Familial pancreatic cancer--current knowledge.
    Bartsch DK; Gress TM; Langer P
    Nat Rev Gastroenterol Hepatol; 2012 Aug; 9(8):445-53. PubMed ID: 22664588
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.